Education
About Us
Working with TipRanks
Follow Us
Ascelia Pharma AB (SE:ACE)
:ACE
ACE Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.89 - kr5.00
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.03M
Market Cap
kr489.63M
Enterprise Valuekr443.83M
Total Cash (Recent Filing)kr75.26M
Total Debt (Recent Filing)kr25.40M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 21, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding116,025,530
10 Day Avg. Volume943,685
30 Day Avg. Volume1,026,326
Financial Highlights & Ratios
PEG Ratio-3.81
Price to Book (P/B)5.18
Price to Sales (P/S)0.00
P/FCF Ratio-7.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ascelia Pharma AB News
PremiumCompany Announcements
Ascelia Pharma Advances Orviglance Towards FDA Submission
PremiumCompany Announcements
Ascelia Pharma’s AGM: Key Resolutions and Strategic Authorizations
PremiumPre-Earnings
Is 7ZA a Buy, Before Earnings?
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr1.89 and its highest was kr5.00 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr489.63M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 21, 2025 which is in 35 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 16, 2025. The company reported -kr0.2 earnings per share for the quarter, the consensus estimate of -kr0.2 by kr0.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate is -0.1.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 116,025,530 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.2 in its last earnings report, expectations of -kr0.2. Following the earnings report the stock price went down -2.097%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (ACE) is a Swedish specialty pharmaceutical company focused on the development of novel drugs that address unmet medical needs, primarily in the field of oncology. The company's lead product candidate, Orviglance (formerly known as Mangoral), is an oral imaging drug designed to enhance the visualization of liver metastases in patients with impaired kidney function undergoing MRI scans. Ascelia Pharma operates within the pharmaceutical sector, with a commitment to improving diagnostic procedures and treatment options for cancer patients.
Technical Analysis
Immunicum AB
―
Isofol Medical AB
―
NextCell Pharma AB
―
Xbrane Biopharma AB
―
Xintela AB
―